Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FATES
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD22-SPDB-DM4
|
|||||
| Synonyms |
Anti CD22 SPDB DM4
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.8-2.0
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD22 Anti-ody (LC-K149C)
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Ravtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.